Alkem Laboratories Ltd.
ALKEM · NSE · Healthcare
With a 20% margin of safety, our buy-below price is ₹4,272.5.
Piotroski F-score 3/9 — quality of earnings & balance sheet.
Investability checklist
- ✓ROE above 15%17.6%
- ✓Low debt (D/E < 0.5)0.14x
- ✓Positive free cash flow
- ✓Revenue growth > 10%15%
- ✕Earnings growing-23%
- ✓Net margin ≥ 10%15.6%
- ✓Current ratio > 1.52.55
- ✓Below our fair value
- ✕Margin of safety ≥ 20%
- ✕Above 200-day average
- ✕Above 50-day average
- –Positive 1-year return
- ✓Altman Z in safe zoneZ 7.67
- ✕Piotroski ≥ 73/9
1-year price
EOD · 2026-06-15Our scores
Key fundamentals
SWOT snapshot
Strengths
- •Lightly leveraged balance sheet.
- •Healthy profit margin (15.6%).
- •Financially solid — Altman Z 7.67.
Weaknesses
- •Price below its 200-day moving average (downtrend).
- •Weak Piotroski score (3/9).
Opportunities
- •Revenue growing (15% YoY).
- •Trading in our value buy zone versus sector peers.
Threats
- •Earnings contracting year on year.
About Alkem Laboratories Ltd.
Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, and biosimilars, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective, gastroenterology, pain management, iron deficiency, diabetology, central nervou
More in Healthcare
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.